Review of health economic analyses in atopic dermatitis: how diverse is the literature?

References

• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
   PubMed Web of Science ®Google Scholar
• Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Radtke MA, Schafer I, Glaeske G, et al. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151–157.
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40.
   PubMed Web of Science ®Google Scholar
• Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–286.
   PubMed Web of Science ®Google Scholar
• Lange S, Zschocke I, Seidenglanz K, et al. Predictors of the quality of life in patients with atopic dermatitis. Dermatol Psychosom. 2000;1(2):66–70.
   Google Scholar
• Norreslet LB, Ebbehoj NE, Ellekilde Bonde JP, et al. The impact of atopic dermatitis on work life - a systematic review. J Eur Acad Dermatol Venereol. 2018;32(1):23–38.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357.
   PubMed Web of Science ®Google Scholar
• Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–1321.
   PubMed Web of Science ®Google Scholar
• Laird M, Lo Sicco K. Defining and measuring the scope of atopic dermatitis. Adv Exp Med Biol. 2017;1027:93–104.
   PubMed Web of Science ®Google Scholar
• Blome C, Radtke MA, Eissing L, et al. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol. 2016;17(2):163–169.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Augustin M, Zschocke I, Lange S, et al. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt. 1999;50(10):715–722.
   PubMed Web of Science ®Google Scholar
• Werfel T, Claes C, Kulp W, et al. Therapy of atopic eczema. GMS Health Technol Assess. 2006;2:Doc19.
   PubMedGoogle Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of Dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045–1060.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• Steinke S, Langenbruch A, Stander S, et al. Therapeutic benefits in atopic dermatitis care from the patients’ perspective: results of the German national health care study ‘atopic health’. Dermatology. 2014;228(4):350–359.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong -HC-H, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3S1):S28–S36.
   PubMed Web of Science ®Google Scholar
• Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–671.
   PubMed Web of Science ®Google Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–337.
   PubMedGoogle Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York (NY): Oxford University Press; 2005.
   Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ. 1986;5(1):1–30.
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the american academy of dermatology association and the society for investigative dermatology. J Am Acad Dermatol. 2006;55(3):490–500.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Qureshi AA, Amand C, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018;6(4):1342–1348.
   PubMed Web of Science ®Google Scholar
• Narla S, Hsu DY, Thyssen JP, et al. Inpatient financial burden of atopic dermatitis in the United States. J Invest Dermatol. 2017;137(7):1461–1467.
   PubMed Web of Science ®Google Scholar
• Filanovsky MG, Pootongkam S, Tamburro JE, et al. The financial and emotional impact of atopic dermatitis on children and their families portions of the study were presented at the 40th annual meeting of the society for pediatric dermatology, Coeur d’Alene, Idaho, July 9- 12,2014. J Pediatr. 2016;169:284.
   PubMed Web of Science ®Google Scholar
• Kim C, Park KY, Ahn S, et al. Economic impact of atopic dermatitis in Korean patients. Ann Dermatol. 2015;27(3):298–305.
   PubMed Web of Science ®Google Scholar
• Misery L, Ansolabehere X, Grandfils N, et al. Nine-year follow-up of children with atopic dermatitis by general practitioners. Dermatology. 2014;228(4):344–349.
   PubMed Web of Science ®Google Scholar
• Alanne S, Maskunitty A, Nermes M, et al. Costs of allergic diseases from birth to two years in Finland. Public Health. 2012;126(10):866–872.
   PubMed Web of Science ®Google Scholar
• Ngamphaiboon J, Kongnakorn T, Detzel P, et al. Direct medical costs associated with atopic diseases among young children in Thailand. J Med Econ. 2012;15(6):1025–1035.
   PubMedGoogle Scholar
• Schmitt J. Medical care and health-economic relevance of atopic eczema. [German]. Allergologie. 2010;33(6):279–288.
   Web of Science ®Google Scholar
• Anandan C, Gupta R, Simpson CR, et al. Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med. 2009;102(10):431–442.
   PubMed Web of Science ®Google Scholar
• Arnold RJ, Donnelly A, Altieri L, et al. Assessment of outcomes and parental effect on quality-of-life endpoints in the management of atopic dermatitis. Manag Care Interface. 2007;20(2):18–23.
   PubMedGoogle Scholar
• Fowler JF, Duh MS, Rovba L, et al. The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective. Manag Care Interface. 2007;20(10):26–32.
   PubMedGoogle Scholar
• Suh D-C, Sung J, Gause D, et al. Economic burden of atopic manifestations in patients with atopic dermatitis - Analysis of administrative claims. J Manag Care Pharm. 2007;13(9):778–789.
   PubMed Web of Science ®Google Scholar
• Barbeau M, Lalonde H. Burden of atopic dermatitis in Canada. Int J Dermatol. 2006;45(1):31–36.
   PubMed Web of Science ®Google Scholar
• Ricci G, Bendandi B, Pagliara L, et al. Atopic dermatitis in Italian children: evaluation of its economic impact. J Pediatr Health Care. 2006;20(5):311–315.
   PubMedGoogle Scholar
• Ehlken B, Mohrenschlager M, Kugland B, et al. Cost-of-illness study in patients suffering from atopic eczema in Germany. [German]. Hautarzt. 2005;56(12):1144–1151.
   PubMed Web of Science ®Google Scholar
• Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol. 2004;45(1):16–22.
   PubMedGoogle Scholar
• Weinmann S, Kamtsiuris P, Henke K-D, et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol. 2003;14(1):18–26.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46(3):361–370.
   PubMed Web of Science ®Google Scholar
• Fivenson D, Arnold RJG, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm. 2002;8(5):333–342.
   PubMedGoogle Scholar
• Verboom P, Hakkaart-Van L, Sturkenboom M, et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol. 2002;147(4):716–724.
   PubMed Web of Science ®Google Scholar
• Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol. 2001;144(3):514–522.
   PubMed Web of Science ®Google Scholar
• Rathjen D, Thiele K, Staab D, et al. The estimated costs of neurodermatitis in children. [German]. Z Gesundh Wiss. 2000;8(1):14–25.
   Google Scholar
• Gieler U, Hohmann M, Niemeier V, et al. Cost evaluation in atopic eczema. J Dermatolog Treat. 1999;10:S15–S20.
   Web of Science ®Google Scholar
• Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159–162.
   PubMed Web of Science ®Google Scholar
• Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol. 1996;135(1):20–23.
   PubMed Web of Science ®Google Scholar
• Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol. 1993;28:699–703.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Miao R, Wang L, et al. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, medicare, and medi-cal databases. Adv Ther. 2017;34(8):1989–2006.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226–232.
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 national health and wellness survey. J Am Acad Dermatol. 2018;78(1):54–61.e1.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Health care utilization, patient costs, and access to care in US adults with eczema: a population-based study. JAMA Dermatol. 2015;151(7):743–752.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Carrascosa Carrillo JM. Economic impact of atopic dermatitis in adults: a population-based study (IDEA study). Actas Dermosifiliogr. 2018;109(1):35–46.
   PubMed Web of Science ®Google Scholar
• Handa S, Jain N, Narang T. Cost of care of atopic dermatitis in India. Indian J Dermatol. 2015;60(2):213.
   PubMed Web of Science ®Google Scholar
• Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13–14.
   PubMedGoogle Scholar
• Hammer-Helmich L, Linneberg A, Thomsen SF, et al. Health service use among children with and without eczema, asthma, and hay fever. Clin Epidemiol. 2016;8:341–349.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bego-Le-Bagousse G, Eckert L, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther (Heidelb). 2017;7(4):493–505.
   PubMed Web of Science ®Google Scholar
• Norrlid H, Hjalte F, Lundqvist A, et al. Cost-effectiveness of maintenance treatment with a barrier-strengthening moisturizing cream in patients with atopic dermatitis in Finland, Norway and Sweden. Acta Derm Venereol. 2016;96(2):173–176.
   PubMed Web of Science ®Google Scholar
• Tang M, Leong KF, Ou L-S, et al. Cost-effectiveness study of pediatric atopic dermatitis in Asia: atopiclair vs. Regular emollient (AD-ATOP). J Drugs Dermatol. 2015;14(2):169–175.
   PubMed Web of Science ®Google Scholar
• Roll S, Reinhold T, Pach D, et al. Comparative effectiveness of homoeopathic vs. conventional therapy in usual care of atopic eczema in children: long-term medical and economic outcomes. PLoS One. 2013;8(1):e54973.
   PubMed Web of Science ®Google Scholar
• van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, et al. E-health in caring for patients with atopic dermatitis: a randomized controlled cost-effectiveness study of internet-guided monitoring and online self-management training. Br J Dermatol. 2012;166(5):1060–1068.
   PubMed Web of Science ®Google Scholar
• Healy E, Bentley A, Fidler C, et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. national health service) perspective. Br J Dermatol. 2011;164(2):387–395.
   PubMed Web of Science ®Google Scholar
• Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: A randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531–537.
   PubMed Web of Science ®Google Scholar
• Schuttelaar M, Vermeulen KM, Coenraads PJ. Costs and cost-effectiveness analysis of treatment in children with eczema by nurse practitioner vs. dermatologist: results of a randomized, controlled trial and a review of international costs. Br J Dermatol. 2011;165(3):600–611.
   PubMed Web of Science ®Google Scholar
• Hjalte F, Asseburg C, Tennvall GR. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden - with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol. 2010;24(4):474–480.
   PubMed Web of Science ®Google Scholar
• Poole CD, Chambers C, Allsopp R, et al. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. J Eur Acad Dermatol Venereol. 2010;24(6):674–678.
   PubMed Web of Science ®Google Scholar
• Haubrock M, Daschner A, Diepgen T, et al. Health economic aspects of prevention measures in the framework of a research project for improved prevention and provision concepts for children and adolescents suffering from neurodermatitis: a national, prospective multi-centre project for the development and evaluation of a standardised patient training course programme (GADIS). [German]. Gesundheitsokonomie Qualitatsmanagement. 2009;14(4):191–199.
   Google Scholar
• Witt CM, Brinkhaus B, Pach D, et al. Homoeopathic versus conventional therapy for atopic eczema in children: medical and economic results. Dermatology. 2009;219(4):329–340.
   PubMed Web of Science ®Google Scholar
• Hjelmgren J, Svensson A, Jorgensen ET, et al. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol. 2007;156(5):913–921.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol. 2006;7(2):133–139.
   PubMed Web of Science ®Google Scholar
• Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol. 2006;154(6):1137–1146.
   PubMed Web of Science ®Google Scholar
• Garside R, Stein K, Castelnuovo E, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess (Rockv). 2005;9(29):iii–122.
   Web of Science ®Google Scholar
• Green C, Colquitt JL, Kirby J, et al. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol. 2005;152(1):130–141.
   PubMed Web of Science ®Google Scholar
• Coyle D, Barbeau M. Cost effectiveness of elidel in the management of patients with atopic dermatitis in Canada. J Cutan Med Surg. 2004;8(6):405–410.
   PubMed Web of Science ®Google Scholar
• Salo H, Pekurinen M, Granlund H, et al. An economic evaluation of intermittent cyclosporin a therapy versus UVAB phototherapy in the treatment of patients with severe atopic dermatitis. Acta Derm Venereol. 2004;84(2):138–141.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2003;48(4):553–563.
   PubMed Web of Science ®Google Scholar
• de Tiedra A, Mercadal J, Lozano R. Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study. Pharmacoeconomics. 1997;12(2 Pt 1):193–208.
   PubMed Web of Science ®Google Scholar
• Thomas KS, Bradshaw LE, Sach TH, et al. Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess (Rockv). 2017;21(16):1–259.
   Web of Science ®Google Scholar
• Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008;159(6):1322–1330.
   PubMed Web of Science ®Google Scholar
• Thomas KS, Koller K, Dean T, et al. A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET). Health Technol Assess (Rockv). 2011;15(8):5–156.
   Web of Science ®Google Scholar
• Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ. 2003;6:1–14.
   Google Scholar
• Taneja C, Antaya RJ, Berger A, et al. Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis. J Drugs Dermatol. 2010;9(4):372–376.
   PubMed Web of Science ®Google Scholar
• Ostermann JK, Witt CM, Reinhold T. A retrospective cost-analysis of additional homeopathic treatment in Germany: longterm economic outcomes. PLoS One. 2017;12(9):e0182897.
   PubMed Web of Science ®Google Scholar
• Beal BT, Prodanovic E, Kuo JE, et al. Impact of a pediatric dermatology service on emergency department utilization for children with dermatitis. Pediatr Dermatol. 2016;33(1):69–74.
   PubMed Web of Science ®Google Scholar
• Ridd MJ, Garfield K, Gaunt DM, et al. Choice of Moisturiser for Eczema Treatment (COMET): feasibility study of a randomised controlled parallel group trial in children recruited from primary care. BMJ Open. 2016;6(11):e012021.
   PubMed Web of Science ®Google Scholar
• Ostermann JK, Reinhold T, Witt CM. Can additional homeopathic treatment save costs? A retrospective cost-analysis based on 44500 insured persons. PLoS One. 2015;10(7):e0134657.
   PubMed Web of Science ®Google Scholar
• Mason JM, Carr J, Buckley C, et al. Improved emollient use reduces atopic eczema symptoms and is cost neutral in infants: before-and-after evaluation of a multifaceted educational support programme. BMC Dermatol. 2013;13:7.
   PubMedGoogle Scholar
• Thaci D, Chambers C, Sidhu M, et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010;24(9):1040–1046.
   PubMed Web of Science ®Google Scholar
• Bergmo TS, Wangberg SC, Schopf TR, et al. Web-based consultations for parents of children with atopic dermatitis: results of a randomized controlled trial. Acta Paediatr. 2009;98(2):316–320.
   PubMed Web of Science ®Google Scholar
• Ehlayel MS, Bener A. Does montelukast reduce the treatment cost in children with moderately severe atopic dermatitis. Curr Pediatr Res. 2008;12:1–4.
   Google Scholar
• Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Abramovits W, Paller A, et al. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol. 2007;6(4):416–423.
   PubMedGoogle Scholar
• Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm. 2007;13(4):349–359.
   PubMed Web of Science ®Google Scholar
• Staab D, von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002;13(2):84–90.
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Haschke F, Farah B, et al. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children. J Med Econ. 2012;15(2):394–408.
   PubMedGoogle Scholar
• Botteman MF, Bhanegaonkar AJ, Horodniceanu EG, et al. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore. Singapore Med J. 2017;59(8):439–448.
   PubMed Web of Science ®Google Scholar
• Xu S, Immaneni S, Hazen GB, et al. Cost-effectiveness of prophylactic moisturization for atopic dermatitis. JAMA Pediatr. 2017;171(2):e163909.
   PubMed Web of Science ®Google Scholar
• Bhanegaonkar A, Horodniceanu EG, Ji X, et al. Economic burden of atopic dermatitis in high-risk infants receiving cow’s milk or partially hydrolyzed 100% whey-based formula. J Pediatr. 2015;166(5):1145.
   PubMed Web of Science ®Google Scholar
• Bhanegaonkar AJ, Horodniceanu EG, Abdul Latiff AH, et al. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. Asia Pac Allergy. 2015;5(2):84–97.
   PubMed Web of Science ®Google Scholar
• Botteman M, Detzel P. Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in high-risk urban infants in Southeast Asia. Ann Nutr Metab. 2015;66:26–32.
   PubMed Web of Science ®Google Scholar
• Bhanegaonkar AJ, Horodniceanu EG, Gonzalez R, et al. Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in at-risk urban Filipino infants. Value Health Reg Issues. 2014;3(1):124–135.
   PubMedGoogle Scholar
• Kiencke P, Viehmann K, Rychlik R. Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children. Eur J Health Econ. 2013;14(6):995–1002.
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Belli D, Farah B, et al. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children. J Med Econ. 2012;15(2):378–393.
   PubMedGoogle Scholar
• Mertens J, Stock S, Lungen M, et al. Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany. Pediatr Allergy Immunol. 2012;23(6):597–604.
   PubMed Web of Science ®Google Scholar
• Su J, Prescott S, Sinn J, et al. Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia. J Med Econ. 2012;15(6):1064–1077.
   PubMedGoogle Scholar
• Iskedjian M, Dupont C, Spieldenner J, et al. Economic evaluation of a 100 whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children. Curr Med Res Opin. 2010;26(11):2607–2626.
   PubMed Web of Science ®Google Scholar
• Lenoir-Wijnkoop I, van Aalderen WM, Boehm G, et al. Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands. Eur J Health Econ. 2012;13(1):101–110.
   PubMed Web of Science ®Google Scholar
• Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm. 2005;11(1):66–73.
   PubMedGoogle Scholar
• Komura Y, Kogure T, Kawahara K, et al. Economic assessment of actual prescription of drugs for treatment of atopic dermatitis: differences between dermatology and pediatrics in large-scale receipt data. J Dermatol. 2017;45(2):165–174.
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66–72.e11.
   PubMed Web of Science ®Google Scholar
• Narla S, Hsu DY, Thyssen JP, et al. Predictors of hospitalization, length of stay, and costs of care among adult and pediatric inpatients with atopic dermatitis in the United States. Dermatitis. 2017;29(4):22–31.
   Google Scholar